Anteris Provides Promising Results from DurAVR™ THV First in Human Study

Tuesday, 11 June 2024, 07:16
The latest data update from Anteris regarding the DurAVR™ transcatheter heart valve (THV) presented at the New York Valves 2024 conference shows significant progress and potentially positive outcomes. The study highlights important milestones achieved in the first in human trial, indicating advancements in the field of transcatheter valve technology. Anteris is demonstrating a commitment to innovation and excellence in cardiovascular healthcare, with the potential to redefine treatment standards.
https://store.livarava.com/2318579f-27de-11ef-a412-9d5fa15a64d8.jpg
Anteris Provides Promising Results from DurAVR™ THV First in Human Study

Anteris Provides Data Update on DurAVR™ THV Study at New York Valves 2024

The latest data update from Anteris regarding the DurAVR™ transcatheter heart valve (THV) presented at the New York Valves 2024 conference shows significant progress and potentially positive outcomes.

Promising Results in First in Human Study

The study highlights important milestones achieved, indicating advancements in the field of transcatheter valve technology.

Anteris is demonstrating a commitment to innovation and excellence in cardiovascular healthcare, with the potential to redefine treatment standards.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe